Use of Ebola Vaccine: Expansion of Recommendations of the Advisory Committee on Immunization Practices To Include Two Additional Populations - United States, 2021

On December 19, 2019, the Food and Drug Administration (FDA) approved rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO, Merck) for the prevention of Ebola virus disease (EVD) caused by infection with Ebola virus, species Zaire ebolavirus, in adults aged ≥18 years. In February 2020, the Advisory Committee on Im...

Full description

Saved in:
Bibliographic Details
Published in:MMWR. Morbidity and mortality weekly report 2022-02, Vol.71 (8), p.290-292
Main Authors: Malenfant, Jason H, Joyce, Allison, Choi, Mary J, Cossaboom, Caitlin M, Whitesell, Amy N, Harcourt, Brian H, Atmar, Robert L, Villanueva, Julie M, Bell, Beth P, Hahn, Christine, Loehr, Jamie, Davey, Richard T, Sprecher, Armand, Kraft, Colleen S, Shoemaker, Trevor, Montgomery, Joel M, Helfand, Rita, Damon, Inger K, Frey, Sharon E, Chen, Wilbur H
Format: Article
Language:English
Subjects:
Adult
Advisory Committees
Centers for Disease Control and Prevention, U.S
Drug approval
Ebola Vaccines - administration & dosage
Ebola virus
Ebola virus infections
Ebolavirus
Exposure
Fever
Health aspects
Health Personnel
Health Planning Guidelines
Health risks
Hemorrhagic Fever, Ebola - prevention & control
Humans
Illnesses
Immunization
Infection
Infections
Infectious diseases
International economic relations
Laboratory Personnel
Medical laboratories
Medical personnel
Occupational exposure
Occupational Exposure - prevention & control
Occupational health
Pathogens
Pharmaceutical industry
Polls & surveys
Populations
Prevention
Public health
Risk
United States - epidemiology
Vaccination
Vaccines
Viral diseases
Virus diseases
Viruses
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c498t-b46c50a54fc76bac0aa9dac746d91ae8aab1e4e0459a5a5b164e11c19fad4deb3
cites cdi_FETCH-LOGICAL-c498t-b46c50a54fc76bac0aa9dac746d91ae8aab1e4e0459a5a5b164e11c19fad4deb3
container_end_page 292
container_issue 8
container_start_page 290
container_title MMWR. Morbidity and mortality weekly report
container_volume 71
creator Malenfant, Jason H
Joyce, Allison
Choi, Mary J
Cossaboom, Caitlin M
Whitesell, Amy N
Harcourt, Brian H
Atmar, Robert L
Villanueva, Julie M
Bell, Beth P
Hahn, Christine
Loehr, Jamie
Davey, Richard T
Sprecher, Armand
Kraft, Colleen S
Shoemaker, Trevor
Montgomery, Joel M
Helfand, Rita
Damon, Inger K
Frey, Sharon E
Chen, Wilbur H
description On December 19, 2019, the Food and Drug Administration (FDA) approved rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO, Merck) for the prevention of Ebola virus disease (EVD) caused by infection with Ebola virus, species Zaire ebolavirus, in adults aged ≥18 years. In February 2020, the Advisory Committee on Immunization Practices (ACIP) recommended preexposure vaccination with ERVEBO for adults aged ≥18 years in the United States who are at highest risk for potential occupational exposure to Ebola virus because they are responding to an outbreak of EVD, work as health care personnel at federally designated Ebola treatment centers in the United States, or work as laboratorians or other staff members at biosafety level 4 facilities in the United States (1).
doi_str_mv 10.15585/mmwr.mm7108a2
format article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_reports_2756125980</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A696218030</galeid><sourcerecordid>A696218030</sourcerecordid><originalsourceid>FETCH-LOGICAL-c498t-b46c50a54fc76bac0aa9dac746d91ae8aab1e4e0459a5a5b164e11c19fad4deb3</originalsourceid><addsrcrecordid>eNptklFv0zAUhSMEYmXwyiOyQEI8kBIndprwVlUFKk1ighbxFt3YN6tRbHe2wxg_h1-K03WITbUfLJ37nSPr6iTJc5pNKecVf6f1lZtqPaNZBfmDZEI542lV0u8Pk0lGWZ3mtOYnyRPvf2TjKbLHyUnB8ywvOJskfzYeie3IsrU9kG8ghDL4nix_7cB4Zc04-4LCao1GQoiKH6WwRTKXP5W37pos4lSFgDHIkJXWg1G_9yg5dyCCEujJ2pKVEf0gkayvbPRKNRLQk3O7G_pDcko2RgWU5GuAgP4tid-kT5NHHfQenx3e02TzYblefErPPn9cLeZnqWB1FdKWlYJnwFknZmULIgOoJYgZK2VNASuAliLDjPEaOPCWlgwpFbTuQDKJbXGavLzJ3Tl7OaAPjcOddcE3-YyXNOd1lUXozT1IKy-w78GgHSJaFkXFZrxmEX11g15Aj40ynQ1xHSPezMu6zGmMGwPTI9QFGnTQW4OdivIdfnqEj1eiVuKo4fV_hi1CH7be9sN-40eThbPeO-yanVMa3HVDs2ZftmYsW3Nbtmh4cdjF0GqU__DbdhV_ATNP0EM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2756125980</pqid></control><display><type>article</type><title>Use of Ebola Vaccine: Expansion of Recommendations of the Advisory Committee on Immunization Practices To Include Two Additional Populations - United States, 2021</title><source>Open Access: PubMed Central</source><source>Social Science Premium Collection (Proquest) (PQ_SDU_P3)</source><creator>Malenfant, Jason H ; Joyce, Allison ; Choi, Mary J ; Cossaboom, Caitlin M ; Whitesell, Amy N ; Harcourt, Brian H ; Atmar, Robert L ; Villanueva, Julie M ; Bell, Beth P ; Hahn, Christine ; Loehr, Jamie ; Davey, Richard T ; Sprecher, Armand ; Kraft, Colleen S ; Shoemaker, Trevor ; Montgomery, Joel M ; Helfand, Rita ; Damon, Inger K ; Frey, Sharon E ; Chen, Wilbur H</creator><creatorcontrib>Malenfant, Jason H ; Joyce, Allison ; Choi, Mary J ; Cossaboom, Caitlin M ; Whitesell, Amy N ; Harcourt, Brian H ; Atmar, Robert L ; Villanueva, Julie M ; Bell, Beth P ; Hahn, Christine ; Loehr, Jamie ; Davey, Richard T ; Sprecher, Armand ; Kraft, Colleen S ; Shoemaker, Trevor ; Montgomery, Joel M ; Helfand, Rita ; Damon, Inger K ; Frey, Sharon E ; Chen, Wilbur H</creatorcontrib><description>On December 19, 2019, the Food and Drug Administration (FDA) approved rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO, Merck) for the prevention of Ebola virus disease (EVD) caused by infection with Ebola virus, species Zaire ebolavirus, in adults aged ≥18 years. In February 2020, the Advisory Committee on Immunization Practices (ACIP) recommended preexposure vaccination with ERVEBO for adults aged ≥18 years in the United States who are at highest risk for potential occupational exposure to Ebola virus because they are responding to an outbreak of EVD, work as health care personnel at federally designated Ebola treatment centers in the United States, or work as laboratorians or other staff members at biosafety level 4 facilities in the United States (1).</description><identifier>ISSN: 0149-2195</identifier><identifier>EISSN: 1545-861X</identifier><identifier>DOI: 10.15585/mmwr.mm7108a2</identifier><identifier>PMID: 35202354</identifier><language>eng</language><publisher>United States: U.S. Government Printing Office</publisher><subject>Adult ; Advisory Committees ; Centers for Disease Control and Prevention, U.S ; Drug approval ; Ebola Vaccines - administration &amp; dosage ; Ebola virus ; Ebola virus infections ; Ebolavirus ; Exposure ; Fever ; Health aspects ; Health Personnel ; Health Planning Guidelines ; Health risks ; Hemorrhagic Fever, Ebola - prevention &amp; control ; Humans ; Illnesses ; Immunization ; Infection ; Infections ; Infectious diseases ; International economic relations ; Laboratory Personnel ; Medical laboratories ; Medical personnel ; Occupational exposure ; Occupational Exposure - prevention &amp; control ; Occupational health ; Pathogens ; Pharmaceutical industry ; Polls &amp; surveys ; Populations ; Prevention ; Public health ; Risk ; United States - epidemiology ; Vaccination ; Vaccines ; Viral diseases ; Virus diseases ; Viruses ; Womens health</subject><ispartof>MMWR. Morbidity and mortality weekly report, 2022-02, Vol.71 (8), p.290-292</ispartof><rights>COPYRIGHT 2022 U.S. Government Printing Office</rights><rights>Published 2022. This article is a U.S. Government work and is in the public domain in the USA.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c498t-b46c50a54fc76bac0aa9dac746d91ae8aab1e4e0459a5a5b164e11c19fad4deb3</citedby><cites>FETCH-LOGICAL-c498t-b46c50a54fc76bac0aa9dac746d91ae8aab1e4e0459a5a5b164e11c19fad4deb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2756125980?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,776,780,21494,27903,27904,33591,33593,43712</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35202354$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Malenfant, Jason H</creatorcontrib><creatorcontrib>Joyce, Allison</creatorcontrib><creatorcontrib>Choi, Mary J</creatorcontrib><creatorcontrib>Cossaboom, Caitlin M</creatorcontrib><creatorcontrib>Whitesell, Amy N</creatorcontrib><creatorcontrib>Harcourt, Brian H</creatorcontrib><creatorcontrib>Atmar, Robert L</creatorcontrib><creatorcontrib>Villanueva, Julie M</creatorcontrib><creatorcontrib>Bell, Beth P</creatorcontrib><creatorcontrib>Hahn, Christine</creatorcontrib><creatorcontrib>Loehr, Jamie</creatorcontrib><creatorcontrib>Davey, Richard T</creatorcontrib><creatorcontrib>Sprecher, Armand</creatorcontrib><creatorcontrib>Kraft, Colleen S</creatorcontrib><creatorcontrib>Shoemaker, Trevor</creatorcontrib><creatorcontrib>Montgomery, Joel M</creatorcontrib><creatorcontrib>Helfand, Rita</creatorcontrib><creatorcontrib>Damon, Inger K</creatorcontrib><creatorcontrib>Frey, Sharon E</creatorcontrib><creatorcontrib>Chen, Wilbur H</creatorcontrib><title>Use of Ebola Vaccine: Expansion of Recommendations of the Advisory Committee on Immunization Practices To Include Two Additional Populations - United States, 2021</title><title>MMWR. Morbidity and mortality weekly report</title><addtitle>MMWR Morb Mortal Wkly Rep</addtitle><description>On December 19, 2019, the Food and Drug Administration (FDA) approved rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO, Merck) for the prevention of Ebola virus disease (EVD) caused by infection with Ebola virus, species Zaire ebolavirus, in adults aged ≥18 years. In February 2020, the Advisory Committee on Immunization Practices (ACIP) recommended preexposure vaccination with ERVEBO for adults aged ≥18 years in the United States who are at highest risk for potential occupational exposure to Ebola virus because they are responding to an outbreak of EVD, work as health care personnel at federally designated Ebola treatment centers in the United States, or work as laboratorians or other staff members at biosafety level 4 facilities in the United States (1).</description><subject>Adult</subject><subject>Advisory Committees</subject><subject>Centers for Disease Control and Prevention, U.S</subject><subject>Drug approval</subject><subject>Ebola Vaccines - administration &amp; dosage</subject><subject>Ebola virus</subject><subject>Ebola virus infections</subject><subject>Ebolavirus</subject><subject>Exposure</subject><subject>Fever</subject><subject>Health aspects</subject><subject>Health Personnel</subject><subject>Health Planning Guidelines</subject><subject>Health risks</subject><subject>Hemorrhagic Fever, Ebola - prevention &amp; control</subject><subject>Humans</subject><subject>Illnesses</subject><subject>Immunization</subject><subject>Infection</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>International economic relations</subject><subject>Laboratory Personnel</subject><subject>Medical laboratories</subject><subject>Medical personnel</subject><subject>Occupational exposure</subject><subject>Occupational Exposure - prevention &amp; control</subject><subject>Occupational health</subject><subject>Pathogens</subject><subject>Pharmaceutical industry</subject><subject>Polls &amp; surveys</subject><subject>Populations</subject><subject>Prevention</subject><subject>Public health</subject><subject>Risk</subject><subject>United States - epidemiology</subject><subject>Vaccination</subject><subject>Vaccines</subject><subject>Viral diseases</subject><subject>Virus diseases</subject><subject>Viruses</subject><subject>Womens health</subject><issn>0149-2195</issn><issn>1545-861X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>ALSLI</sourceid><sourceid>M2R</sourceid><recordid>eNptklFv0zAUhSMEYmXwyiOyQEI8kBIndprwVlUFKk1ighbxFt3YN6tRbHe2wxg_h1-K03WITbUfLJ37nSPr6iTJc5pNKecVf6f1lZtqPaNZBfmDZEI542lV0u8Pk0lGWZ3mtOYnyRPvf2TjKbLHyUnB8ywvOJskfzYeie3IsrU9kG8ghDL4nix_7cB4Zc04-4LCao1GQoiKH6WwRTKXP5W37pos4lSFgDHIkJXWg1G_9yg5dyCCEujJ2pKVEf0gkayvbPRKNRLQk3O7G_pDcko2RgWU5GuAgP4tid-kT5NHHfQenx3e02TzYblefErPPn9cLeZnqWB1FdKWlYJnwFknZmULIgOoJYgZK2VNASuAliLDjPEaOPCWlgwpFbTuQDKJbXGavLzJ3Tl7OaAPjcOddcE3-YyXNOd1lUXozT1IKy-w78GgHSJaFkXFZrxmEX11g15Aj40ynQ1xHSPezMu6zGmMGwPTI9QFGnTQW4OdivIdfnqEj1eiVuKo4fV_hi1CH7be9sN-40eThbPeO-yanVMa3HVDs2ZftmYsW3Nbtmh4cdjF0GqU__DbdhV_ATNP0EM</recordid><startdate>20220225</startdate><enddate>20220225</enddate><creator>Malenfant, Jason H</creator><creator>Joyce, Allison</creator><creator>Choi, Mary J</creator><creator>Cossaboom, Caitlin M</creator><creator>Whitesell, Amy N</creator><creator>Harcourt, Brian H</creator><creator>Atmar, Robert L</creator><creator>Villanueva, Julie M</creator><creator>Bell, Beth P</creator><creator>Hahn, Christine</creator><creator>Loehr, Jamie</creator><creator>Davey, Richard T</creator><creator>Sprecher, Armand</creator><creator>Kraft, Colleen S</creator><creator>Shoemaker, Trevor</creator><creator>Montgomery, Joel M</creator><creator>Helfand, Rita</creator><creator>Damon, Inger K</creator><creator>Frey, Sharon E</creator><creator>Chen, Wilbur H</creator><general>U.S. Government Printing Office</general><general>U.S. Center for Disease Control</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>0-V</scope><scope>3V.</scope><scope>4T-</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>88F</scope><scope>88J</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AN0</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M1Q</scope><scope>M2O</scope><scope>M2R</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PATMY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PYCSY</scope><scope>Q9U</scope><scope>S0X</scope></search><sort><creationdate>20220225</creationdate><title>Use of Ebola Vaccine: Expansion of Recommendations of the Advisory Committee on Immunization Practices To Include Two Additional Populations - United States, 2021</title><author>Malenfant, Jason H ; Joyce, Allison ; Choi, Mary J ; Cossaboom, Caitlin M ; Whitesell, Amy N ; Harcourt, Brian H ; Atmar, Robert L ; Villanueva, Julie M ; Bell, Beth P ; Hahn, Christine ; Loehr, Jamie ; Davey, Richard T ; Sprecher, Armand ; Kraft, Colleen S ; Shoemaker, Trevor ; Montgomery, Joel M ; Helfand, Rita ; Damon, Inger K ; Frey, Sharon E ; Chen, Wilbur H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c498t-b46c50a54fc76bac0aa9dac746d91ae8aab1e4e0459a5a5b164e11c19fad4deb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adult</topic><topic>Advisory Committees</topic><topic>Centers for Disease Control and Prevention, U.S</topic><topic>Drug approval</topic><topic>Ebola Vaccines - administration &amp; dosage</topic><topic>Ebola virus</topic><topic>Ebola virus infections</topic><topic>Ebolavirus</topic><topic>Exposure</topic><topic>Fever</topic><topic>Health aspects</topic><topic>Health Personnel</topic><topic>Health Planning Guidelines</topic><topic>Health risks</topic><topic>Hemorrhagic Fever, Ebola - prevention &amp; control</topic><topic>Humans</topic><topic>Illnesses</topic><topic>Immunization</topic><topic>Infection</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>International economic relations</topic><topic>Laboratory Personnel</topic><topic>Medical laboratories</topic><topic>Medical personnel</topic><topic>Occupational exposure</topic><topic>Occupational Exposure - prevention &amp; control</topic><topic>Occupational health</topic><topic>Pathogens</topic><topic>Pharmaceutical industry</topic><topic>Polls &amp; surveys</topic><topic>Populations</topic><topic>Prevention</topic><topic>Public health</topic><topic>Risk</topic><topic>United States - epidemiology</topic><topic>Vaccination</topic><topic>Vaccines</topic><topic>Viral diseases</topic><topic>Virus diseases</topic><topic>Viruses</topic><topic>Womens health</topic><toplevel>online_resources</toplevel><creatorcontrib>Malenfant, Jason H</creatorcontrib><creatorcontrib>Joyce, Allison</creatorcontrib><creatorcontrib>Choi, Mary J</creatorcontrib><creatorcontrib>Cossaboom, Caitlin M</creatorcontrib><creatorcontrib>Whitesell, Amy N</creatorcontrib><creatorcontrib>Harcourt, Brian H</creatorcontrib><creatorcontrib>Atmar, Robert L</creatorcontrib><creatorcontrib>Villanueva, Julie M</creatorcontrib><creatorcontrib>Bell, Beth P</creatorcontrib><creatorcontrib>Hahn, Christine</creatorcontrib><creatorcontrib>Loehr, Jamie</creatorcontrib><creatorcontrib>Davey, Richard T</creatorcontrib><creatorcontrib>Sprecher, Armand</creatorcontrib><creatorcontrib>Kraft, Colleen S</creatorcontrib><creatorcontrib>Shoemaker, Trevor</creatorcontrib><creatorcontrib>Montgomery, Joel M</creatorcontrib><creatorcontrib>Helfand, Rita</creatorcontrib><creatorcontrib>Damon, Inger K</creatorcontrib><creatorcontrib>Frey, Sharon E</creatorcontrib><creatorcontrib>Chen, Wilbur H</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>ProQuest Social Sciences Premium Collection【Remote access available】</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>ProQuest Nursing and Allied Health Source</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Military Database (Alumni Edition)</collection><collection>Social Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>Social Science Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>British Nursing Database</collection><collection>Agricultural &amp; Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>Consumer Health Database</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Family Health</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest Healthcare Administration Database</collection><collection>PML(ProQuest Medical Library)</collection><collection>Military Database</collection><collection>ProQuest research library</collection><collection>ProQuest Social Science Journals</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Environmental Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Environmental Science Collection</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><jtitle>MMWR. Morbidity and mortality weekly report</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Malenfant, Jason H</au><au>Joyce, Allison</au><au>Choi, Mary J</au><au>Cossaboom, Caitlin M</au><au>Whitesell, Amy N</au><au>Harcourt, Brian H</au><au>Atmar, Robert L</au><au>Villanueva, Julie M</au><au>Bell, Beth P</au><au>Hahn, Christine</au><au>Loehr, Jamie</au><au>Davey, Richard T</au><au>Sprecher, Armand</au><au>Kraft, Colleen S</au><au>Shoemaker, Trevor</au><au>Montgomery, Joel M</au><au>Helfand, Rita</au><au>Damon, Inger K</au><au>Frey, Sharon E</au><au>Chen, Wilbur H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of Ebola Vaccine: Expansion of Recommendations of the Advisory Committee on Immunization Practices To Include Two Additional Populations - United States, 2021</atitle><jtitle>MMWR. Morbidity and mortality weekly report</jtitle><addtitle>MMWR Morb Mortal Wkly Rep</addtitle><date>2022-02-25</date><risdate>2022</risdate><volume>71</volume><issue>8</issue><spage>290</spage><epage>292</epage><pages>290-292</pages><issn>0149-2195</issn><eissn>1545-861X</eissn><abstract>On December 19, 2019, the Food and Drug Administration (FDA) approved rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO, Merck) for the prevention of Ebola virus disease (EVD) caused by infection with Ebola virus, species Zaire ebolavirus, in adults aged ≥18 years. In February 2020, the Advisory Committee on Immunization Practices (ACIP) recommended preexposure vaccination with ERVEBO for adults aged ≥18 years in the United States who are at highest risk for potential occupational exposure to Ebola virus because they are responding to an outbreak of EVD, work as health care personnel at federally designated Ebola treatment centers in the United States, or work as laboratorians or other staff members at biosafety level 4 facilities in the United States (1).</abstract><cop>United States</cop><pub>U.S. Government Printing Office</pub><pmid>35202354</pmid><doi>10.15585/mmwr.mm7108a2</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0149-2195
ispartof MMWR. Morbidity and mortality weekly report, 2022-02, Vol.71 (8), p.290-292
issn 0149-2195
1545-861X
language eng
recordid cdi_proquest_reports_2756125980
source Open Access: PubMed Central; Social Science Premium Collection (Proquest) (PQ_SDU_P3)
subjects Adult
Advisory Committees
Centers for Disease Control and Prevention, U.S
Drug approval
Ebola Vaccines - administration & dosage
Ebola virus
Ebola virus infections
Ebolavirus
Exposure
Fever
Health aspects
Health Personnel
Health Planning Guidelines
Health risks
Hemorrhagic Fever, Ebola - prevention & control
Humans
Illnesses
Immunization
Infection
Infections
Infectious diseases
International economic relations
Laboratory Personnel
Medical laboratories
Medical personnel
Occupational exposure
Occupational Exposure - prevention & control
Occupational health
Pathogens
Pharmaceutical industry
Polls & surveys
Populations
Prevention
Public health
Risk
United States - epidemiology
Vaccination
Vaccines
Viral diseases
Virus diseases
Viruses
Womens health
title Use of Ebola Vaccine: Expansion of Recommendations of the Advisory Committee on Immunization Practices To Include Two Additional Populations - United States, 2021
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T09%3A47%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20Ebola%20Vaccine:%20Expansion%20of%20Recommendations%20of%20the%20Advisory%20Committee%20on%20Immunization%20Practices%20To%20Include%20Two%20Additional%20Populations%20-%20United%20States,%202021&rft.jtitle=MMWR.%20Morbidity%20and%20mortality%20weekly%20report&rft.au=Malenfant,%20Jason%20H&rft.date=2022-02-25&rft.volume=71&rft.issue=8&rft.spage=290&rft.epage=292&rft.pages=290-292&rft.issn=0149-2195&rft.eissn=1545-861X&rft_id=info:doi/10.15585/mmwr.mm7108a2&rft_dat=%3Cgale_proqu%3EA696218030%3C/gale_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c498t-b46c50a54fc76bac0aa9dac746d91ae8aab1e4e0459a5a5b164e11c19fad4deb3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2756125980&rft_id=info:pmid/35202354&rft_galeid=A696218030&rfr_iscdi=true